Preview : Published ahead of advance online publication Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain

This is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication. NPG are providing this early version of the manuscript as a service to our customers. The manuscript will undergo copyediting, typesetting and a proof review before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

[1]  Livio Luongo,et al.  Endocannabinoids and neuropathic pain: focus on neuron–glia and endocannabinoid–neurotrophin interactions , 2014, The European journal of neuroscience.

[2]  Irene Tracey,et al.  Pain vulnerability: a neurobiological perspective , 2014, Nature Neuroscience.

[3]  D. Piomelli,et al.  Peripheral gating of pain signals by endogenous lipid mediators , 2014, Nature Neuroscience.

[4]  V. Marzo,et al.  Endocannabinoids: A unique opportunity to develop multitarget analgesics , 2013, PAIN®.

[5]  Sachin Patel,et al.  Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses , 2013, Biology of Mood & Anxiety Disorders.

[6]  R. Treede,et al.  Injection of nerve growth factor into a low back muscle induces long-lasting latent hypersensitivity in rat dorsal horn neurons , 2013, PAIN®.

[7]  S. Chattarji,et al.  Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure , 2013, Molecular Psychiatry.

[8]  D. Selley,et al.  Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[9]  B. Cravatt,et al.  Dual Inhibition of Endocannabinoid Catabolic Enzymes Produces Enhanced Antiwithdrawal Effects in Morphine-Dependent Mice , 2013, Neuropsychopharmacology.

[10]  A. Alpár,et al.  Nerve growth factor scales endocannabinoid signaling by regulating monoacylglycerol lipase turnover in developing cholinergic neurons , 2013, Proceedings of the National Academy of Sciences.

[11]  B. Lutz,et al.  Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission , 2012, Neuropsychopharmacology.

[12]  Carl Y. Saab,et al.  Pain-related changes in the brain: diagnostic and therapeutic potentials , 2012, Trends in Neurosciences.

[13]  M. Schmelz,et al.  NGF-evoked sensitization of muscle fascia nociceptors in humans , 2012, PAIN®.

[14]  M. Häring,et al.  Genetic Dissection of the Role of Cannabinoid Type-1 Receptors in the Emotional Consequences of Repeated Social Stress in Mice , 2012, Neuropsychopharmacology.

[15]  J. Long,et al.  Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice. , 2012, ACS chemical neuroscience.

[16]  D. Nomura,et al.  Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation , 2011, Science.

[17]  A. Hohmann,et al.  Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. , 2011, Pharmacological research.

[18]  F. Basile,et al.  Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. , 2011, Biochemical pharmacology.

[19]  L. Arendt-Nielsen,et al.  Local Pain and Spreading Hyperalgesia Induced by Intramuscular Injection of Nerve Growth Factor Are Not Reduced by Local Anesthesia of the Muscle , 2011, The Clinical journal of pain.

[20]  F. Luo,et al.  Increased thermal and mechanical nociceptive thresholds in rats with depressive-like behaviors , 2010, Brain Research.

[21]  Peter T. Nguyen,et al.  Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system , 2010, Nature Neuroscience.

[22]  D. Centonze,et al.  Preservation of Striatal Cannabinoid CB1 Receptor Function Correlates with the Antianxiety Effects of Fatty Acid Amide Hydrolase Inhibition , 2010, Molecular Pharmacology.

[23]  J. Vlaeyen,et al.  Treatments Addressing Pain-Related Fear and Anxiety in Patients with Chronic Musculoskeletal Pain: A Preliminary Review , 2010, Cognitive behaviour therapy.

[24]  A. Cattaneo.  Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. , 2010, Current opinion in molecular therapeutics.

[25]  S. Waxman,et al.  Unilateral focal burn injury is followed by long-lasting bilateral allodynia and neuronal hyperexcitability in spinal cord dorsal horn. , 2010, The journal of pain : official journal of the American Pain Society.

[26]  D. Nomura,et al.  Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo , 2009, Proceedings of the National Academy of Sciences.

[27]  M. McCarthy,et al.  Differential effects of chronic unpredictable stress on hippocampal CB1 receptors in male and female rats , 2009, Behavioural Brain Research.

[28]  J. Long,et al.  Blockade of 2-Arachidonoylglycerol Hydrolysis by Selective Monoacylglycerol Lipase Inhibitor 4-Nitrophenyl 4-(Dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances Retrograde Endocannabinoid Signaling , 2009, Journal of Pharmacology and Experimental Therapeutics.

[29]  D. Boger,et al.  Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain , 2009, Journal of Pharmacology and Experimental Therapeutics.

[30]  B. Lutz.  Endocannabinoid signals in the control of emotion. , 2009, Current opinion in pharmacology.

[31]  Benjamin F. Cravatt,et al.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects , 2008, Nature chemical biology.

[32]  B. Lutz,et al.  Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors , 2008, Neuropharmacology.

[33]  R. Mangieri,et al.  Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress , 2007, Biological Psychiatry.

[34]  M. Jann,et al.  Antidepressant Agents for the Treatment of Chronic Pain and Depression , 2007, Pharmacotherapy.

[35]  D. Barrett,et al.  Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain , 2006, The Journal of Neuroscience.

[36]  Wim E Crusio,et al.  Effects of unpredictable chronic mild stress on anxiety and depression-like behavior in mice , 2006, Behavioural Brain Research.

[37]  Daniele Piomelli,et al.  Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). , 2006, CNS drug reviews.

[38]  T. Unger,et al.  Excitatory and modulatory effects of inflammatory cytokines and neurotrophins on mechanosensitive group IV muscle afferents in the rat , 2005, Pain.

[39]  W. Farquhar-Smith,et al.  A Novel Neuroimmune Mechanism in Cannabinoid-mediated Attenuation of Nerve Growth Factor–induced Hyperalgesia , 2003, Anesthesiology.

[40]  K. Sluka,et al.  Unilateral intramuscular injections of acidic saline produce a bilateral, long‐lasting hyperalgesia , 2001, Muscle & nerve.

[41]  T. Yaksh,et al.  Quantitative assessment of tactile allodynia in the rat paw , 1994, Journal of Neuroscience Methods.

[42]  Shafiqur Rahman,et al.  Analgesic activity of the different fractions of the aerial parts of Commelina benghalensis Linn. , 2010 .

[43]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.